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Identity 
Other names: D52, N8L, PC-1, PrLZ, hD52 
HGNC (Hugo): TPD52 
Location: 8q21.13 
Local order: On the reverse strand. 
DNA/RNA 
Description 
The TPD52 gene is found on chromosome 8, at 
location 81109658-81246391 bp. It is composed of at 
least 9 exons spanning a genomic region of 138.88 kb 
and the open reading frame of the coding region is 555 
bp. 
Transcription 
Experimentally, an increase in TPD52 protein or 
mRNA transcript levels has been demonstrated or 
predicted following a number of different types of 
stimuli, such as hormone receptor activation(using 
dihydrotestosterone (DePrimo et al., 2002), estradiol 
(Byrne et al., 1996) and the synthetic androgens R1881 
(DePrimo et al., 2002; Nelson et al., 2002; Rubin et al., 
2004) and methyltrienolone (Wang et al., 2004)), 
immune receptor activation (toll-like receptor 4 (TLR-
4) using bacterial Lipopolysaccharide (LPS) and 
triggering receptors expressed on myeloid cells 1 
(TREM-1) using anti-TREM-1 cross-linking antibody 
(Dower et al., 2008)), Erbb2 over-expression (Landis et 
al., 2005), Platelet-Derived Growth Factor (PDGF) 
signalling (Ma et al., 2005) and BRCA1 tumor 
suppressor (containing a single amino acid substitution 
specifically at Ser1841Asn) expression (Crugliano et 
al., 2007). A decrease in TPD52 transcript levels ha
been observed or predicted following treatment with 
the differentiating agent 12-O-tetradecanoylphorbol-
13-acetate (TPA) (Byrne et al., 1996), myc onco-
protein overexpression (Guo et al., 2000) and MyoD 
gene knockdown (Asakura et al., 2007). 
Pseudogene 
No human pseudogene for TPD52 has been identified 
(see Pseudogene In Family). 
Protein 
Description 
The TPD52 gene encodes multiple proteins, 
predominantly TPD52 (184 aa, isoform 3, accession no. 
NP_005070.1) and PrLZ/PC-1 (224 aa, isoform 1, 
accession no. NP_001020423.1). Both are encoded by 
6 exons, with the first exon being unique to each 
isoform. They share a coiled-coil motif located towards 
the N-terminus but possess alternate N-terminal 
domains. Since TPD52 is more ubiquitously expressed 
than PrLZ (for TPD52 expression, see Byrne et al., 
1995 and Chen et al., 1996; for PrLZ expression, see 
Wang et al., 2004), TPD52 will be the primary focus of 
this summary. 
TPD52 is a 184-amino acid polypeptide with a 
predicted molecular mass of 19.8 kDa. The protein is 
indicated to be largely hydrophilic, has a calculated 
isoelectric point of 4.75, and contains an identified 
phosphorylation site at Serine 136 (Chew et al., 2008; 
Thomas et al., 2010). 
Using glutaraldehyde cross-linking, Chen et al. (1997) 
showed that TPD52 is able to bind itself (also shown by 
Byrne et al., 1998; Sathasivam et al., 2001, and Thomas 
et al., 2001). Byrne et al. (1998) also showed that 
TPD52 binds the related TPD52L1 and TPD52L2 
proteins. These authors proposed that TPD52 may exert 
and/or regulate its activities through interaction with 
itself and its related proteins and that the coiled-coil 
motif predicted within the TPD52 protein is necessary 
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for interactions (Byrne et al., 1998). A subsequent 
analysis indicated that C-terminal regions may also 
facilitate and/or stabilise these interactions (Sathasivam 
et al., 2001). 
The first heterologous binding partner identified for 
TPD52 was the proteolipid MAL2 (Wilson et al., 
2001), which is similar to MAL, an integral component 
of the apical transport machinery in polarised celltypes 
(Martin-Belmonte et al., 1998; Puertollano et al., 1999; 
Cheong et al., 1999). MAL2 was shown to be a binding 
partner for TPD52 using the yeast two-hybrid system 
(Wilson et al., 2001) and more recently to co-
immunoprecipitate with TPD52 using Myc-MAL2 
overexpressing MCF-10A breast cancer cells (Fanayan 
et al., 2009). 
TPD52 also binds Annexin VI, which is involved in 
membrane trafficking, and this binding is Ca2+- 
dependent (Thomas et al., 2002; Tiacci et al., 2005). 
TPD52 (along with Tip47, Rab5, Rab6 and Rab9) co-
immunoprecipitated with the bacterial product ExoS, as 
shown by a study which examined the transport of 
ExoS from plasma membrane to perinuclear regions 
(Zhang et al., 2007a). 
Expression 
Early studies using Northern blot analysis undertaken 
by Byrne et al. (1995) showed strong expression of 
TPD52 transcripts in colon and kidney tissues. Chen et 
al. (1996) used the same technique to identify 
comparatively high TPD52 transcript levels in kidney, 
prostate, small intestine and kidney, as well as 
moderate levels in brain, liver, placenta, pancreas 
epithelia, and low levels in heart, lung, ovary, 
peripheral blood leukocyte, skeletal muscle, spleen, 
testis, and thymus tissues. Chen et al. (1997) followed 
up with immunohistochemistry and multiple tissue 
western blot analysis indicating strong detection of 
TPD52 protein in colon and kidney, moderate levels in 
brain and liver tissue, and low levels in heart, lung and 
skeletal muscle. Groblewski et al. (1999) used western 
blotting and immunofluorescence studies to identify 
high levels of TPD52 protein in colon epithelia and 
small intestine epithelia, as well as moderate exprssion 
in the lacrimal gland, pancreas, parotid gland, stomach 
epithelia and submandibular gland. More recently, 
Wang et al. (2004) identified high levels of the PrLZ 
transcript in prostate using a multiple tissue exprssion 
array, whilst Tiacci et al. (2005) found high levels of 
TPD52 protein via immunofluorescence in B cells 
(including plasma cells) and colon tissue, and moderate 
levels in stomach and pancreas epithelia. 
Localisation 
TPD52 is partitioned between soluble and insoluble 
cellular protein fractions (Groblewski et al., 1999; 
Balleine et al., 2000), suggesting that TPD52 may hve 
multiple subcellular locations. TPD52 is abundant 
around secretory granules in the apical cytoplasm of 
epithelial cells of exocrine glands, gastrointestinal 
tissues and in cultured mucosal T84 cells of the rat 
(Groblewski et al., 1999; Kaspar et al., 2003a). Kaspar 
et al. (2003a) also showed that TPD52 exists in 
perinuclear regions of T84 cells, whilst Thomas et al. 
(2004) showed that TPD52 exists within or around both 
endocytic and exocytic compartments within rat 
pancreatic acinar cells. Using breast cancer samples, 
immunohistochemical analysis by Balleine et al. (2000) 
revealed TPD52 staining within the cytoplasm and less 
frequently in the perinucleus, whilst benign epithelial 
elements displayed little or no staining. Myeloma cells 
also strongly expressed TPD52 in the cytoplasm 
(Tiacci et al., 2005). 
Function 
At a subcellular level, TPD52 appears to be involved in 
plasma membrane-based exocytic (Thomas et al., 2001; 
Kaspar et al., 2003a; Kaspar et al., 2003b; Chew et al., 
2008) and endocytic functions (Thomas et al., 2004), 
and trafficking within the exo- and endocytic pathways 
(Thomas et al., 2002; Thomas et al., 2004). At a 
cellular level, TPD52 has been shown to promote 
proliferation (Lewis et al., 2007; Zhang et al., 2007b; 
Shehata et al., 2008a; Li et al., 2009) and tissue 
invasion (Lewis et al., 2007), as well as B-cell 
maturation (Tiacci et al., 2005). However, a clear link
between TPD52's subcellular and cellular influences 
has yet to be established. 
TPD52 was initially predicted to function as a calcium-
sensitive signalling molecule, since rabbit TPD52 is 
phosphorylated in gastric parietal cells upon 
cholinergic stimulation (Parente et al., 1996). At least 
two phosphorylation events for human and rat TPD52 
have been demonstrated (Groblewski et al., 1996; 
Kaspar et al., 2003a; 2003b) and more are predicted 
(Olsen et al., 2006; Molina et al., 2007). Using mass 
spectrometry and site-directed mutagenesis, Chew et al.
(2008) showed that the calcium/calmodulin-dependent 
phosphorylation of TPD52 on serine residue 136 may 
be mediated by CAMK2delta6. Significantly, the time-
course of such phosphorylation was found to correlate 
with exocytosis, suggesting that TPD52 may promote 
exocytosis following phosphorylation. Thomas et al. 
(2010) recently showed that this phosphorylation of 
TPD52 caused an increase of LAMP-1 exocytosis from 
CHO-K1 cells. This had earlier been suggested in 
studies involving stimulation of pancreatic (using 
cholecystokinin-octapeptide) and colonic (using 
carbachol) secretion in rat acinar and mucosal T-84 
cells, respectively (Kaspar et al., 2003a; 2003b). On par 
with this, amylase was shown to be released from rat 
pancreatic acinar cells in a calcium-dependent manner, 
following the introduction of recombinant TPD52 
(Thomas et al., 2001). Furthermore, TGF-beta1 was 
found to be secreted from stably transfected mouse 
Tpd52-expressing 3T3 fibroblasts (Lewis et al., 2007). 
However, it has not been determined if TPD52 is 
directly involved with the above-mentioned release of 
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TGF-beta1 or if this is perhaps a downstream 
consequence of TPD52 expression. 
TPD52 binds Annexin VI (Thomas et al., 2002; Tiacci 
et al., 2005) and MAL2 (Wilson et al., 2001) which 
have been implicated in clathrin-mediated endocytosis 
(Kamal et al., 1998; Thomas et al., 2002) and indirect 
apical transcytosis (de Marco et al., 2002), respectiv ly. 
Using CCK-8 treatment in pancreatic acinar cells, 
Thomas et al. (2004) showed TPD52 to localise to early 
endosomes and the limiting membrane of zymogen 
granules, suggesting that TPD52 may play a role in 
protein and phospholipid distribution within the 
secretory pathway. They also recently examined 
LAMP-1 trafficking and AP-3/TPD52 co-localisation 
in CHO-K1 cells which suggested TPD52 may 
participate in lysosome-like vesicle formation (post-
golgi) as well as endocytic retrieval (Thomas et al.,
2010). TPD52's potential endocytic involvement was 
also demonstrated through its co-immunoprecipitation 
with the bacterial product ExoS (along with Tip47, 
Rab5, Rab6 and Rab9), perhaps enabling the transport 
of the bacterial product ExoS from endosome to golgi 
and perinuclear regions (Zhang et al., 2007a). TPD52 
also binds family member TPD52L1, which itself has 
been implicated in the regulation of SNARE complexes 
on early endosomes (Proux-Gillardeaux et al., 2003). 
Exogenous expression of TPD52 isoforms in various 
cell lines has produced increases in anchorage-
independent colony formation (Lewis et al., 2007; 
Zhang et al., 2007b; Shehata et al., 2008a), 
proliferation (Lewis et al., 2007; Zhang et al., 2007b; 
Shehata et al., 2008a; Li et al., 2009), metastatic ab lity 
post-inoculation (Lewis et al., 2007), tumor volume 
post-inoculation (Zhang et al., 2007b; Li et al., 2009) 
and migration/invasion rate (Li et al., 2009). Also, a 
decrease in TPD52 level following siRNA treatment 
caused an increase in apoptosis in the SK-BR-3 breast 
cancer cell line (Shehata et al., 2008a). Zhang et al. 
(2007b) showed that stable transfection of TPD52 in 
LNCaP and its derivative androgen-independent C4-2 
prostate cancer cell lines results in the phosphorylation 
of signalling intermediates that are also implicated in 
producing the above-mentioned phenotypes, namely 
AKT, Raf and GSK-3beta. The increased 
phosphorylation of AKT has since been confirmed by 
Ummanni et al. (2008), who also examined the LNCaP 
cell line. 
Homology 
Subsequent to the characterisation of TPD52 in 1995 
(Byrne et al., 1995), there have been three  
related genes described. These are TPD52L1 (D53) 
(Byrne et al., 1996), TPD52L2 (D54) (Nourse et al.,
1998) and NYD-SP25/TPD52L3 (D55) (Cao et al., 
2006). TPD52-like genes share about 50% nucleotide 
sequence homology, and are not similar to proteins of 
known function in any species (Nourse et al., 1998). 
TPD52 and TPD52-like genes appear to have evolved 
from ancestral TPD52-like sequences such as those 
found in Drosophila melanogaster and Caenorhabditis 





Association to diseases (breast neoplasms; carcinoma, 
basal cell; neoplasms; ovarian neoplasms; prostatic 
neoplasms) and proposed to participate in processes 
(anatomical structure morphogenesis, B cell 
differentiation, secretion). 
Disease 
In situ hybridisation and Northern blot studies first 
revealed TPD52 overexpression in breast cancer (Byrne 
et al., 1995). Chen et al. (1996, 1997) also found 
TPD52 mRNA/protein to be expressed in breast cancer 
derived cell lines, as well as those derived from lung 
cancer, colon cancer, pancreatic cancer, prostate 
cancer, kidney cancer, leukemia and Burkitt's 
lymphoma. Other more recent investigations have 
confirmed TPD52 or PrLZ RNA/protein 
overexpression in prostate cancer (Rubin et al., 2004; 
Wang et al., 2004). 
TPD52 overexpression has also been predicted via 
expression microarray studies for prostate (Rhodes et 
al., 2002; Ahram et al., 2002; Best et al., 2003), ovarian 
(Shridhar et al., 2001), endometrial (Risinger et al.,
2003; Cai et al., 2007), hepatocellular (Chen et al., 
2002), lung (Garber et al., 2001; Bhattacharjee et al., 
2001), melanoma (Bittner et al., 2000; Zhou et al.,
2004; Hoek, 2007; Roesch et al., 2007) and testicular 
germ cell tumours (Sperger et al., 2003; Skotheim et 
al., 2005; Korkola et al., 2006; Skotheim et al., 2006; 
McIntyre et al., 2007; Korkola et al., 2008). TPD52 
protein overexpression has been confirmed in 
melanoma (Roesch et al., 2007) and testicular germ c ll 
tumours (Alagaratnam et al., 2009). 
Prognosis 
Expression microarray studies have revealed TPD52 
gene overexpression to be associated with adverse 
outcome for patients with breast cancer (Adler et al., 
2006; Liu et al., 2007), prostate cancer (Bismar et al., 
2006) and mantle cell lymphoma (Ma et al., 2007). 
Higher levels of TPD52 expression amongst breast 
cancer patients has also been shown to be associated 
with reduced overall patient survival (Shehata et al., 
2008a). 
Cytogenetics 
Using TPD52 expression and relative TPD52 copy 
number studies in breast specimens, Balleine et al. 
(2000) first proposed TPD52 as a target gene driving 
increased copy number of 8q21. Similar studies have 
since identified an association between TPD52 copy 
number gain and TPD52 expression in prostate cancer 
(Rubin et al., 2004; Wang et al., 2004) and ovarian 
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cancer (Byrne et al., 2005). TPD52 has also been fou d 
to be amplified and overexpressed in multiple myeloma 
(Largo et al., 2006), pancreatic cancer xenografts 
(Loukopolous et al., 2007) and testicular germ cell 
tumours (Skotheim et al., 2006; Mcintyre et al., 2007; 
Korkola et al., 2008). However, TPD52 overexpression 
may also occur in the absence of gene amplification or 
gain (Balleine et al., 2000; Adelaide et al., 2007). 
Oncogenesis 
An increase in TPD52 expression has been found to be 
a comparatively early event in breast (Porter et al., 
2003; Yu et al., 2004; Shehata et al., 2008a), prostate 
(Rubin et al., 2004; Wang et al., 2004) and ovarian 
cancer (Byrne et al., 2005). Other analyses also suggest 
that increased TPD52 expression may be a marker of 
tumour predisposition (Sims et al., 2007) or very early 
preneoplastic changes (Byrne et al., 2005). High 
TPD52 expression may also contribute to the 
development of primary carcinomas (Rubin et al., 
2004; Wang et al., 2004; Bismar et al., 2006; Wang et 
al., 2007). The prevalence of high TPD52 expression in 
early and late stages of cancer suggest that it may
contribute to tumour initiation and progression, 
possibly through independent mechanisms. It would be 
expected that TPD52 perturbs fundamental cell 
properties, as TPD52 overexpression exists in tumours 
of different cellular origins (Shehata et al., 2008b - 
review). Linking the ever-increasing experimental dta 
obtained using TPD52-transfected cell lines with 
clinical studies should assist in forming more reliable 
predictions as to how TPD52 contributes to 
carcinogenesis and/or metastasis. 
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